TARPON SPRINGS, Fla., May 8, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage ...

Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors in the world, and its incidence and mortality have increased year by year. HCC research has increasingly focused on ...

In March 2026, Boehringer Ingelheim achieved a research milestone under the agreement for SZN-413, reflecting a positive outcome of the IND-enabling GLP toxicology study. The Company received a $5.0 ...

Hepatocellular carcinoma (HCC) is one of the deadliest cancers globally, with increasing incidence and mortality rates. It arises from chronic liver diseases, including hepatitis B or C infections, ...

“Choosing wisely” in oncology: The example of surveillance positron emission tomography-computed tomography (PET-CT) for patients with colorectal cancer (CRC) treated with curative intent. This is an ...

A new research perspective was published in Oncotarget's Volume 14 on February 7, 2023, entitled, "WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go?" Novel biological ...

Researchers at the University of Illinois, Urbana-Champaign, developed an approach using blue light to activate the Wnt signaling pathway in frog embryos. The pathway plays a wide variety of roles in ...

Mouse Avatar Models of Colorectal Cancer Liver Metastasis: The Molecularly Annotated Platforms for Preclinical Evaluation of Novel Therapeutics Background: Oral squamous cell carcinoma (OSCC) is a ...

A new study reveals why some pancreatic and colorectal tumors resist targeted anti-Wnt drugs and suggests how to overcome it, offering new hope to patients with fully treatment-resistant cancers.